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University of Paris-Sud, CNRS, Orsay, Francef
Combination therapy is rarely used to counter the evolution of resistance in bacterial infections. Expansion of the use of combi-
nation therapy requires knowledge of how drugs interact at inhibitory concentrations. More than 50 years ago, it was noted that,
if bactericidal drugs are most potent with actively dividing cells, then the inhibition of growth induced by a bacteriostatic drug
should result in an overall reduction of efficacy when the drug is used in combination with a bactericidal drug. Our goal here was
to investigate this hypothesis systematically. We first constructed time-kill curves using five different antibiotics at clinically rel-
evant concentrations, and we observed antagonism between bactericidal and bacteriostatic drugs. We extended our investigation
by performing a screen of pairwise combinations of 21 different antibiotics at subinhibitory concentrations, and we found that
strong antagonistic interactions were enriched significantly among combinations of bacteriostatic and bactericidal drugs. Fi-
nally, since our hypothesis relies on phenotypic effects produced by different drug classes, we recreated these experiments in a
microfluidic device and performed time-lapse microscopy to directly observe and quantify the growth and division of individual
cells with controlled antibiotic concentrations. While our single-cell observations supported the antagonism between bacterio-
static and bactericidal drugs, they revealed an unexpected variety of cellular responses to antagonistic drug combinations, sug-
gesting that multiple mechanisms underlie the interactions.
The problem of antibiotic resistance requires a solution thatrelies on more than just the development of new drugs. Patho-
gens have been unrelenting in evolving mechanisms by which to
survive in the face of every drug put on the market. Combination
therapy, i.e., the concurrent application of two or more antibiot-
ics, provides an appealing approach that demands closer assess-
ment as a tool to combat this problem. In the treatment of impor-
tant infectious diseases such as HIV infection, tuberculosis, and
malaria, combination therapy has become the standard approach
precisely to delay the evolution of drug resistance (1–4). In con-
trast, for common acute bacterial infections, combinations of
drugs are prescribed in only a very limited number of cases and
with a different rationale (5). In those specific instances, two drugs
are prescribed for their synergistic effects, that is, for the fact that
their combined effects exceed the sum of their individual effects.
Drug synergy has been demonstrated to result in more-efficient
clearance of infections and to achieve clearance at lower drug con-
centrations (6). Examples of such cases include fusidic acid and
rifampin for the treatment of methicillin-resistant Staphylococcus
aureus infections and trimethoprim and sulfamethoxazole for the
treatment of otitis media (7, 8). Furthermore, recent theoretical
work indicates that synergistic drugs can prevent treatment failure
even when bacteria resistant to one of the drugs are present at the
beginning of therapy (9).
Just as synergy can be exploited to improve treatment, it is
necessary to avoid combinations of drugs that inhibit each other
and may prolong infections. Antagonism, when a drug hinders the
effect of another drug, was reported early in the history of antibi-
otics and continues to function as a warning against indeterminate
treatment (10). In a study of patients with pneumococcal menin-
gitis, 30% of those treated with penicillin alone failed treatment
and died, while 79% of comparable patients who were treated with
the same dosage of penicillin plus chlortetracycline, an antibiotic
that antagonizes penicillin, died (11, 12).
Despite these findings, an increasing number of laboratory
studies indicate that antagonistic drug combinations merit more
investigation as clinical options (13). Recent work in this area
suggests that the different types of interactions have significant
effects on the selection and maintenance of drug resistance muta-
tions. Using a direct competition experiment, Chait and col-
leagues demonstrated how a hyperantagonistic drug combination
was able to select against a bacterial population resistant to one of
the drugs and instead favored the completely sensitive wild type
(14). Furthermore, the rate of adaptation of laboratory bacteria to
multiple drugs has been shown to correlate with the degree of
synergism between individual antibiotics (15). Although antago-
nistic drug combinations are currently eschewed in clinical set-
tings, these studies suggest that antagonism between antibiotics
may aid in devising treatment strategies specifically aimed at de-
laying the emergence of resistance.
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In response to the slow development of new antimicrobials,
there is renewed interest in old drugs that have fallen out of use
due to toxicity or drawbacks in efficacy (16). One approach that
could be implemented to return these drugs to the clinic is to use
an old drug in combination with a current drug (17). The advan-
tages of synergism and the diverse nontrivial effects of antagonism
will play a central role in determining how best to implement
combination therapy in clinical settings.
In order to exploit the potential benefits of combination ther-
apy, we need a better understanding of the circumstances under
which synergism versus antagonism is expected. Determining
how a broader spectrum of drugs interact at inhibitory concentra-
tions and delineating the mechanisms responsible for these effects
could allow for a more-prudent application of antibiotics that
maintains clinical capability and does not sacrifice the future util-
ity of these drugs.
In this study, we asked whether basic pharmacodynamic prop-
erties of all antibiotics can help predict which pairs would result in
antagonism. A widely recognized characteristic of antibiotics is
that they are either bacteriostatic and inhibit growth without kill-
ing the cells or are bactericidal and result in cell killing (18). Thus,
if bactericidal drugs are most potent with actively growing cells, as
hypothesized more than 50 years ago (19, 20), then the inhibition
of growth induced by a bacteriostatic drug should result in a re-
duction of drug efficacy. To test this hypothesis, we determined
the types of interaction between five different drugs at inhibitory
concentrations by estimating death rates using time-kill curves.
We then extended our observations and employed screening
methods to identify effects across pairs of 21 different drugs at
subinhibitory concentrations. Since our hypothesis relies on the
decreased antibiotic susceptibility of slowly growing cells and the
ability of some drugs to influence this state, we repeated our ex-
periments at the level of individual cells using time-lapse micros-
copy, in microfluidic devices, to investigate the cellular dynamics
underlying combined effects of antibiotics.
MATERIALS AND METHODS
High-throughput combination screening experiments. We selected 21
antibiotics with a wide range of mechanisms of action, including drugs
that target cell wall, nucleic acid, protein, and folic acid biosynthesis (Ta-
ble 1). Fresh antibiotic solutions were prepared from powder stocks on a
weekly basis and were filter sterilized before use. All experiments were
conducted in Escherichia coli K-12 (BW25113) in minimal medium sup-
plemented with 0.2% glucose and 0.1% Casamino Acids. Combination
screens were performed in 384-well plates, using a liquid-handling ro-
botic system (Hamilton Star workstation) to improve reproducibility.
The culture volume was 50 l. Each plate contained two different 6-by-6
dose-matrix blocks (one antibiotic in combination with two other antibi-
otics), with 4 replicates each. For each pair of antibiotics, we combined 6
different concentrations of the agents in a serially diluted two-dimen-
sional dose matrix, with dose points being centered on the 50% effective
concentration (EC50) for each antibiotic. The lowest concentration for
each agent was 0 and the highest was above the 90% effective concentra-
tion (EC90) (Table 1). In addition to the dose-matrix blocks, each plate
included 18 wells containing medium without antibiotics (control wells).
Antibiotic sensitivity screens were performed by growing cells over-
night (optical density at 600 nm [OD600], 4) at 30°C, with shaking at 300
rpm, and diluting the cells to an OD equivalent to 0.04. Next, using a
liquid-handling robotic system, cells were transferred into 384-well assay
plates (in the presence of antibiotics) to yield 4  104 cells/well. Assay
plates were incubated for 18 h at 30°C, with shaking at 300 rpm. Bacterial
growth was monitored by measuring the optical density (OD600) of the
liquid cultures at a single time point. Preliminary experiments showed
that a single reading of optical density after 18 h of incubation showed
strong linear correlation with the area under the growth curve (a descrip-
tor of overall inhibitory effect that covers the entire growth period) (21).
Briefly, this was determined using parallel cultures of E. coli grown in ten
384-well microtiter plates under previously stated conditions. Optical
density (OD600) was measured every hour for 24 h, and the areas under the
growth curves were determined using custom MATLAB scripts. For a
number of different ending time points (e.g., 11, 12, and 13 h), we used a
linear regression model to consider whether the last OD measurements
predicted the areas under the growth curves (384  10  3,840 data
points). Plates were prepared as multiple (up to 6) biological replicates,
TABLE 1 List of all antibiotics used in the study
Abbreviation Antibiotic
EC90
a
(g/ml) Main mechanism of action
Bactericidal/bacteriostatic
status
AMP Ampicillin 1.2 Cell wall Bactericidal
PIP Piperacillin 1.5 Cell wall Bactericidal
FOX Cefoxitin 1.4 Cell wall Bactericidal
FOS Fosfomycin 14 Cell wall Bactericidal
LOM Lomefloxacin 0.12 Gyrase Bactericidal
CPR Ciprofloxacin 0.0055 Gyrase Bactericidal
NAL Nalidixic acid 2.3 Gyrase Bactericidal
FSM Fosmidomycin 40 Lipid Bactericidal
NIT Nitrofurantoin 2.4 Multiple mechanisms Bactericidal
AMK Amikacin 3.4 Aminoglycoside, 30S protein synthesis Bactericidal
GEN Gentamicin 0.66 Aminoglycoside, 30S protein synthesis Bactericidal
KAN Kanamycin 3 Aminoglycoside, 30S protein synthesis Bactericidal
TOB Tobramycin 0.85 Aminoglycoside, 30S protein synthesis Bactericidal
STR Streptomycin 4.5 Aminoglycoside, 30S protein synthesis Bactericidal
TET Tetracycline 0.3 30S protein synthesis Bacteriostatic
DOX Doxycycline 0.23 30S protein synthesis Bacteriostatic
CHL Chloramphenicol 1 50S protein synthesis Bacteriostatic
ERY Erythromycin 8.5 50S protein synthesis Bacteriostatic
FUS Fusidic acid 200 50S protein synthesis Bacteriostatic
SLF Sulfamonomethoxine 1.9 Folic acid biosynthesis Bacteriostatic
TRM Trimethoprim 0.4 Folic acid biosynthesis Bacteriostatic
a EC90 represents the concentration of an antibiotic at which 90% of the maximal growth inhibitory effect was observed.
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and those with quality control problems (e.g., growth in control wells was
unusually low or showed large variations or an agent failed to substantially
inhibit growth at high concentrations or strongly inhibited growth at even
low doses) were omitted from further analysis.
We had two reasons to study antibiotic interactions in a standard
minimal medium at a relatively low temperature (30°C). First, because the
culture volume in our study was 50 l, evaporation was a potential con-
cern. To minimize such a confounding effect, 30°C appeared to be an
optimal solution. Second, our experimental setting was similar to that of a
prior study (22), allowing direct comparison of the results of the two
studies.
Data processing and bias correction steps. To overcome any mea-
surement bias caused by within-plate inhomogeneity, we processed the
raw optical density data as follows. We included 18 control wells on each
plate, containing medium without antibiotics and inoculated with E. coli.
We used these wells both to set a baseline for zero inhibition and to
estimate and to eliminate within-plate systematic biases. First we cali-
brated OD values by applying the transformation ODcalibrated  OD 
(0.40449  OD3), to account for the nonlinear association between OD
and cell density at high cell densities (parameters of the calibration for-
mula were derived as in reference 23). Then we calculated relative inhibi-
tion values based on the initial OD (maximum inhibition) and the average
OD of antibiotic-free control wells (maximum growth). To estimate and
to eliminate within-plate spatial effects, first we fitted a linear trend to the
control wells to eliminate spatial gradients. Next, for the residuals, we
employed Gaussian process regression (24) to eliminate the remaining
systematic spatial biases using the control wells. Both steps for bias cor-
rection were carried out in MATLAB.
Identification of interacting antibiotic pairs. Synergistic effects be-
tween combinations of chemicals, resulting in increased benefits or in-
creased toxicity, have important implications across the fields of biomed-
icine (25, 26). Correspondingly, many approaches have been devised to
quantify drug interactions (27). To assess antagonism and synergy be-
tween pairs of antibiotics, we used the Loewe additivity model (28), which
assumes that a drug does not interact with itself. Geometrically, Loewe
additivity can be represented as lines of equally effective dosages (isoboles)
in the two-dimensional linear concentration space for the two drugs. De-
viation of the shape of the isoboles from linearity indicates either synergy
(concave isoboles) or antagonism (convex isoboles). To identify interac-
tions for each pair of antibiotics, first we merged data from replicate dose-
matrix blocks located on the same 384-well plates. Next we fitted sigmoi-
dal dose-response curves (Hill equation) to the single-agent responses
using a maximum likelihood fitting procedure. Based on the single-agent
response curves for the two antibiotics, we calculated the dose-response
relationship for the antibiotic combination expected with the Loewe ad-
ditivity model. To quantify interactions, we determined the concavity of
the set of isoboles inferred from the combination measurements for a
given antibiotic pair (“observed” isoboles). To achieve this, we used a
mathematical transformation to “bend” the linear isoboles expected un-
der the Loewe additivity model to approximate most closely the observed
isoboles (see the report by Cokol and colleagues for a similar approach
[29]). The transformation relies on a single parameter to describe the
concavity of the observed isoboles, which we used as a measure of antibi-
otic interaction. This score is zero in the absence of interaction, negative
for antagonistic pairs, and positive for synergistic pairs. Finally, interac-
tion scores (B) for each antibiotic pair were calculated by taking the me-
dian scores obtained from biological replicates (i.e., independent plates).
Measurement errors of interaction screens were estimated by testing 5
antibiotics for interactions with themselves in multiple replicates (29).
Because under Loewe additivity a drug shows no interaction with itself,
deviation of the interaction score from zero provides an estimate of the
experimental error of interaction measurements. Thus, we considered
two antibiotics as significantly interacting when the score was significantly
different from the mean score for self-self antibiotic combinations. For
calculation of EC50 values, we followed established protocols (30). EC50
refers to the concentration of drug that induces growth inhibition halfway
between the baseline and maximum values after the specified exposure
time.
Antibiotics and concentrations for time-kill and time-lapsemicros-
copy experiments. Determination of the clinical utility of exploiting dif-
ferent interactions between pairs of antibiotics will require extensive test-
ing across organisms, sites of infection, and the drugs used for particular
infections. In contrast, we consider our work a proof-of-principle study,
and future work should confirm potential clinical implications. Although
some of the antibiotics we used have advanced derivatives in the clinic, the
choice of the drugs we used was based on two criteria, i.e., (i) the avail-
ability of very detailed literature on the molecular mechanism of action
and (ii) the possibility for comparison with the results of an older study
(22). Similarly, the antibiotic concentrations used do not reflect clinical
recommendations. For example, although the concentration of erythro-
mycin used in our time-kill and time-lapse microscopy experiments is
higher than that achievable in blood, this drug was included to illustrate
the effect of antagonism between a drug at an inhibitory concentration
and a second drug at a subinhibitory concentration. Although the MIC for
erythromycin in E. coli MG1655 is well above the concentration we used
(500 to 1,000 g/ml), we were interested in determining whether a sub-
inhibitory concentration of this drug was sufficient to antagonize the kill-
ing effect of a second drug whose concentration was above the MIC.
Time-kill curves. Determination of the MICs for the antibiotics used
in the time-kill and time-lapse microscopy studies was carried out using a
broth dilution protocol similar to that recommended by the Clinical and
Laboratory Standards Institute (LB medium was used instead of Mueller-
Hinton broth) (31). The concentrations of the drugs used in the following
experiments represent fractions of the MICs: 25 g/ml streptomycin and
nalidixic acid (2MIC), 12.5 g/ml tetracycline (0.83MIC), 10 g/ml
trimethoprim, (0.66MIC), and 200 g/ml erythromycin (0.4MIC).
Overnight cultures of E. coli MG1655 were diluted 1:10,000 into fresh
prewarmed LB broth and were incubated for 2 h. A further 1:2 dilution
was performed before introduction into flasks containing either a single
antibiotic or a pair of bactericidal and bacteriostatic antibiotics. These were
then incubated at 37°C with shaking and aeration. Samples were taken at
1-h intervals for up to 5 h. Cell densities for each sample were estimated
from colony counts by dilution in phosphate-buffered saline and plating
on LB agar. Each time-kill experiment was performed twice.
Time-lapse microscopy. Specific details of the microfluidic system
used in this study, the mother machine, have been described previously
(32). In brief, this device consists of 4,000 growth channels arranged at
right angles against a large trench, through which growth medium is
passed. Nutrients then diffuse into the channels and flush out growing
cells as they emerge from these channels. An automated microscope stage
allows for the monitoring of multiple fields of view, spanning the entire
device. This method results in the continuous observation of the growth
and division of a large number of individual cells as they experience dif-
ferent antibiotic-containing environments, as well as their survival or
death after the drug has been removed.
Time-lapse microscopy experiments were conducted as follows. E. coli
MG1655 cultures were grown overnight in LB broth at 37°C. On the
following day, 100 l of culture was diluted in 10 ml of fresh prewarmed
LB broth and then was incubated for 2 h at 37°C, with shaking. Eight
milliliters of the resulting culture was centrifuged at 10,000 rpm for 5 to 7
min and resuspended in 20 l of fresh LB broth; 10 l of the cell suspen-
sion was then injected into the mother machine, and the experiment was
initiated when more than 80% of the channels were filled with cells via
diffusion. A syringe pump was used to pass fresh LB broth supplemented
with bovine serum albumin (BSA) and salmon sperm DNA through the
device at a rate of 2 ml/h. BSA and salmon sperm DNA are blocking agents
that are used to bind to the surface of the microfluidic device to prevent
the formation of air bubbles and excessive adhesion of the cells to the
channels. Images were acquired from 15 to 25 fields of view at 6-min
intervals by using an automated Olympus BX81 microscope with an
Antagonistic Antibiotic Interactions
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UPLFN100O2PH/1.3 phase-contrast oil lens. Samples and the micro-
scope were held at 37°C with a cube-and-box incubation system (Life
Imaging Services, Reinach, Switzerland). After at least 4 h of growth in LB
broth, the medium was switched to LB broth containing BSA, salmon
sperm, and either one or two antibiotics. Cells were exposed to this me-
dium for at least 20 h before being switched back to fresh LB broth sup-
plemented with BSA and salmon sperm DNA for up to 10 h. Each exper-
iment involved fields scanned continuously for at least 30 h.
The resulting time-lapse images were then analyzed with a custom-
designed plug-in for ImageJ, to provide information on cell size and divi-
sion rates during the three different phases of the experiment. The first
step of the analysis consists of defining the length of the cell abutting the
end of the channel. The increasing length of the growing cell over succeed-
ing frames is tracked and recorded; division events are also registered
based on cell length. Manual verification and annotation were performed
after every experiment. In this way, we were able to extract quantitative
information on an individual cell’s elongation and division rates. We also
tracked the proportion of cells that survived treatment exposure and were
able to divide again upon the return to an antibiotic-free environment.
The occurrence of filamentation during exposure to the antibiotics eryth-
romycin and nalidixic acid led to elongated cells being pulled out of their
growth channels during flow. For this reason, only channels containing
cells that could be followed for the entirety of the experiment were con-
sidered in the analysis.
RESULTS
Time-kill curves. To quantify interactions between antibiotics at
clinically relevant concentrations, we measured death rates at in-
hibitory drug levels based on time-kill curves. We tested every
possible bactericidal-bacteriostatic pair among five antibiotics at
concentrations above the MIC. The antibiotics used in the time-
kill experiments were selected for their differing mechanisms of
action and because, to the best of our knowledge, there are no
reports of cross-resistance mutations for these drugs in E. coli.
In the presence of a bactericidal drug that alone is capable of
clearing a bacterial population, the addition of a bacteriostatic
drug resulted in a decrease in killing rates and a significant number
of survivors at the end of the experiment (Fig. 1). We also noted
that the degree of antagonism differed depending on the bacteri-
cidal drug employed in the experiment. Acquisition of a resistance
mutation over the course of the time-kill curve experiment could
be a confounding effect explaining the reduced death rate ob-
served in bacterial cultures treated with a bactericidal-bacterio-
static pair. In order to control for this possibility, the colonies
obtained at the end of every time-kill curve experiment were rep-
lica plated on antibiotic-containing plates. We found no evidence
for the evolution of single-drug or multidrug resistance in any
replicate, to any of the drugs used in the experiment (data not
shown). These time-kill curves provide confirmation that the an-
tagonistic interactions found between drugs at inhibitory concen-
trations manifest as decreases in the rate of killing and the pres-
ence of significant proportions of sensitive bacteria at the end of
the experiment.
Systematic exploration of interactions between bactericidal
and bacteriostatic antibiotics. We expanded our observations of
interactions between drugs to a total of 21 antibacterial com-
pounds. These antibiotics cover a wide range of mechanisms of
action, and many of them are widely employed clinically. Their
main targets include DNA synthesis, translational machinery, and
cell wall, folic acid, and lipid biosynthesis (Table 1). We systemat-
ically measured the effects of all pairs of antibiotics on E. coli K-12
growth rates. Specifically, for each pair of antibiotics, we com-
bined 6 different concentrations of the agents in a two-dimen-
sional dose matrix, with dose points being centered on each anti-
biotic’s half-maximal effective concentration (EC50). We used the
Loewe additivity model to assess interactions between antibiotics
(33). In contrast to other models, this model measures drug-drug
interactions based on deviation from a drug-with-itself reference.
According to the Loewe additivity model, if the modes of action
of two drugs are the same, then the drugs show no interaction.
Lines of equal effective dosages (isoboles) are represented in
the two-dimensional linear concentration space of the two
drugs. Deviation of these lines from a linear model indicates
synergism (concave) or antagonism (convex). We introduced
several correction steps to overcome potential measurement
biases due to plate inhomogeneity, and we also developed a rigor-
ous statistical framework to assess the significance of interactions.
Following a previously developed method, we quantified isobole
shapes by measuring concavity (usingB interaction scores), where
B  0 indicates independent effects of the two drugs (linearity)
and B 0 and B 0 indicate antagonism and synergism, respec-
tively (see Materials and Methods). In this work, we focus on
studying the properties of antagonistic antibiotic pairs only; syn-
ergism will be studied elsewhere.
Using a statistical criterion to identify significant interactions
(see Materials and Methods), we found that 61% of the 204 anti-
biotic pairs showed antagonism. The reliability of our results was
confirmed by comparison with a previous systematic drug com-
bination screen performed in E. coli (22). Despite the substantial
differences in the protocols and the underlying assumptions of the
models used in the two studies, interaction scores were well cor-
related (Spearman’s rho, 0.529;P 0.0001) and antagonistic pairs
identified in the previous study tended to have especially low
scores in our screen (Mann-WhitneyU test, P 0.0001). Further-
more, our high-throughput survey correctly identified a well-
characterized antagonism between ciprofloxacin and tetracycline
(34).
The distribution of antagonism is highly nonrandom on the
map of interactions. We compared the B scores for antibiotic in-
teractions in two groups, i.e., antibiotic pairs that target the same
and different cellular subsystems. The comparison revealed that B
scores were especially low for antibiotic pairs targeting different
cellular subsystems (Mann-Whitney U test, P  0.0001). In line
with the expectations of the Loewe model, antibiotic pairs target-
ing the same cellular subsystem rarely showed strong antagonism.
More strikingly, combinations of 30S protein synthesis and
cell wall biosynthesis inhibitors, 50S protein synthesis and gyrase
inhibitors, and cell wall biosynthesis and folic acid synthesis in-
hibitors frequently showed antagonism (P  0.05 for each com-
bination, Fisher’s exact test). A common property of these com-
binations is that a bacteriostatic compound is combined with a
bactericidal agent. To minimize the chance of erroneous classifi-
cation, we used only E. coli-specific information for bactericidal/
bacteriostatic classifications (Table 1). To test more generally
whether antagonism was enriched in bacteriostatic-bactericidal
combinations, we categorized antibiotic pairs according to indi-
vidual antibiotic killing properties, which led to three major
groups, namely, bactericidal-bactericidal, bactericidal-bacterio-
static, and bacteriostatic-bacteriostatic pairs. Strikingly, we found
that antibiotic pairs with exceptionally low B interaction scores,
denoting a high degree of antagonism, were nearly always bacte-
ricidal-bacteriostatic (P 0.0016, Fisher’s exact test) (Fig. 2). This
Ocampo et al.
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result held after exclusion of antibiotic pairs with overlapping cel-
lular targets (P  0.0059). Thus, our data suggest that bacterio-
static agents antagonize the actions of antibiotics that act on grow-
ing cells. This finding is broadly consistent with earlier reports
demonstrating that growth inhibition via nutrient limitation of-
ten diminishes the effects of bactericidal compounds (35, 36).
Comparison of Fig. 1 and 2 also reveals that antagonistic drug
interactions observed beyond the MIC levels are not always appar-
ent at subinhibitory concentrations. Future studies should explore
systematically the mechanisms underlying such differences in
drug interactions.
Single-drug and combination therapy from the perspective
of single cells. Our hypothesis, namely, that bacteriostatic drugs an-
tagonize bactericidal drugs, is independent of the individual molecu-
lar mechanisms of action of the drugs but is reliant on the effects of
antibiotics on the growth dynamics of single cells. Therefore, we rep-
licated the conditions of our time-kill curves in a microfluidic device,
with the goal of directly observing the effects of different antagonistic
drug pairs on single cells. We focused on understanding the differ-
ences in the effects on cell elongation and division of two bacterio-
static drugs that bind to different ribosomal targets, i.e., erythromycin
and tetracycline, with the bactericidal drug nalidixic acid.
FIG 1 Time-kill curves for single-drug and two-drug combinations. Each graph shows the time-kill curve for a bactericidal-bacteriostatic drug pair and the
constituent individual drugs. Error bars represent standard errors of the mean (based on 3 independent replicates) for the number of culturable cells, as measured
in CFU/ml at each time point. Antibiotic concentrations used were 25g/ml nalidixic acid (NAL), 25g/ml streptomycin (STR), 12.5g/ml tetracycline (TET),
200 g/ml erythromycin (ERY), and 10 g/ml trimethoprim (TRM).
Antagonistic Antibiotic Interactions
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FIG 3 Length-time graphs for individual cells before, during, and after antibiotic exposure. At least 20 individual cells per antibiotic treatment were selected for analysis
using custom software; the results of each treatment were collated in one graph, with each line representing the length of a single cell over time. Upward deflections of
these lines denote increases in length, and abrupt downward deflections indicate division events. The shaded section in each graph denotes the period during which
antibiotic-containing medium was used. Lines that end abruptly indicate lysis of the cell under observation. The analysis of a population subjected to erythromycin alone
was problematic due to the formation of long filamentous cells that were drawn out of their growth channels as medium flowed through the primary trench of the device;
this reduced the number of cells available for observation for the entire experiment. Furthermore, in the erythromycin panel, the large fluctuations in cell length indicate
the increased size to which these cells were observed to grow, as well as the continuation of division events. The antibiotic concentrations used were 25g/ml nalidixic
acid, 25g/ml streptomycin, 12.5g/ml tetracycline, 200g/ml erythromycin, and 10g/ml trimethoprim. (A) Cells treated with the bactericidal drug nalidixic acid
either were lysed or were never found to resume division even after the medium had been changed to drug-free broth. (B) Tetracycline was observed to reduce elongation
and completely prevent division during antibiotic exposure, while erythromycin only reduced division rates; this resulted in filamentous cells that were still capable of
division, albeit at lower rates than cells grown in drug-free broth. (C) The combination of nalidixic acid and tetracycline produced growth dynamics similar to those
observed with tetracycline alone. Erythromycin and nalidixic acid, however, induced filamentation and significantly reduced division. Both conditions resulted in large
numbers of cells that were found to resume growth upon a return to drug-free broth.
FIG 2 Systematic exploration of interactions between bactericidal and bacteriostatic antibiotics at subinhibitory concentrations. (A) Heatmap showing pairwise
interactions between 21 antibiotics measured systematically in E. coli. Antibiotics are grouped according to their modes of action, and colors reflect interaction
scores. Negative and positive scores correspond to antagonism (blue) and synergism (red), respectively, according to Loewe additivity criteria. White, missing
data. For antibiotic abbreviations and concentrations, see Table 1. (B) Graph showing that the combination of a bacteriostatic (stat) antibiotic with a bactericidal
(cid) antibiotic has a tendency to show strong antagonism. Antibiotic pairs were categorized according to their individual antibiotic killing properties, leading to
three major groups, i.e., bactericidal-bacteriostatic, bacteriostatic-bacteriostatic, and bactericidal-bactericidal. Antibiotic pairs with interaction scores (B) lower
than1 (i.e., those showing strong antagonism) were significantly more likely to fall in the bactericidal-bacteriostatic category than were the rest of the antibiotic
pairs (P 0.0016, Fisher’s exact test).
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Using a device designed to track the elongation and division of
hundreds of individual cells over a long period (32), we began by
growing E. coli cells in rich medium without antibiotics for at least
4 h, to determine the baseline rates of these cellular processes. This
was followed by exposure to a single drug or pairs of drugs for at
least 16 h. Media were then switched back to drug-free broth for at
least four more hours.
By analyzing the resulting time-lapse images, we captured
quantitative information on the rates of cell elongation and divi-
sion of single cells as they were subjected to different antibiotics
singly or in antagonistic pairs. Furthermore, we monitored the
fates of hundreds of cells from every condition to assess viability
after withdrawal of antibiotic-containing media. While every cell
exposed to bactericidal drugs either was lysed or did not resume
growth by the end of the experiment, at least 30% and up to more
than 80% of individual cells treated with bactericidal-bacterio-
static drug pairs maintained cellular integrity and resumed divi-
sion after replacement of antibiotic-free medium (see Table S1 in
the supplemental material).
We selected at least 20 individual cells per condition for de-
tailed analysis using custom software. We measured each individ-
ual cell’s elongation rate, number of cell length doublings per
hour, and division rate (number of divisions per hour). Figure 3
depicts the lengths of cells for each condition across the entire
duration of the experiment. The graphs reveal qualitative differ-
ences in cellular responses to different antibiotic treatments. Our
time-lapse images revealed contrasting responses to the bacterio-
static drugs tetracycline and erythromycin. As reported previ-
ously, we found that tetracycline exposure reduced cell elongation
and decreased the rate of cell division (24). Erythromycin, how-
ever, reduced only the rate of division, resulting in filamentous
cells that continued to divide. The maximum length depicted in
our plots was constrained by the length of the growth channel in
the microfluidic device, and we were thus unable to measure the
actual size of antibiotic-induced filaments.
To determine whether the strong reductions in elongation and
division observed with tetracycline could similarly antagonize an-
other bactericidal antibiotic with an unrelated mechanism of ac-
tion, we also combined tetracycline with the bactericidal antibi-
otic streptomycin and repeated the analysis. The resulting growth
dynamics are depicted in Fig. S1 in the supplemental material.
In addition to tracking the rates of elongation of cells in the
selected conditions, we extracted the rates of division of individual
cells as they were subjected to different antibiotic-containing me-
dia. In Fig. 4, we present the distributions of the division rates and
elongation rates (as cell length doublings per hour) for each pop-
ulation during the period of exposure to antibiotics. Stasis in cell
division and elongation was observed for individual cells exposed
to the bacteriostatic antibiotic tetracycline. In contrast, treatment
with the bacteriostatic drug erythromycin resulted in decreased
elongation rates and reduced but not completely restricted divi-
sion rates. This produced filamentous cells that were still able to
divide, albeit at lower rates than cells grown in the absence of drug.
The differences in cellular responses observed in the study of
cells exposed to bacteriostatic drugs extended to the results for
antagonistic drug pairs. Cells treated with tetracycline and either
of the bactericidal drugs demonstrated greatly reduced growth
rates and ceased dividing until the antibiotics were withdrawn,
while erythromycin paired with a bactericidal drug halted cell
division, resulting in long filamentous cells that proceeded
with division only after replacement of drug-free medium. Our
time-lapse microscopy experiments thus revealed contrasting
responses of bacteria exposed to drugs belonging to the same
pharmacodynamic class. These differing responses extended to
treatment with different antagonistic drug pairs.
DISCUSSION
The relevance of classifying antibiotics as bacteriostatic or bacte-
ricidal has been questioned due to the reliance of these categories
on drug concentrations and the treated organisms (37). The man-
ner in which these pharmacodynamic properties are used in spe-
cific clinical scenarios is beyond the scope of this paper. Instead,
we propose that this binary classification is a useful initial step in
determining when two drugs in combination would result in
strong antagonism and thus should be evaluated, to exploit the
varied effects of this specific interaction.
The tests set by the Clinical and Laboratory Standards Institute
(31) to determine whether an antibiotic is bacteriostatic or bacte-
ricidal involve assessing the degree of survival of a liquid culture of
bacteria after a certain period of drug exposure. The moderate
killing effect that defines a bacteriostatic agent therefore implies
induction of cellular stasis. Here we show that, while bacteriostatic
drugs result in prevalent patterns of antagonistic interactions with
bactericidal drugs, their effects at the single-cell level may differ
considerably. We found that tetracycline effectively induced stasis
in antibiotic-sensitive bacteria. In contrast, treatment with eryth-
romycin reduced the elongation rate to a similar degree as did
tetracycline, while division rates were not as strongly decreased;
this resulted in long filamentous cells.
The disparities in growth dynamics with similarly antagonistic
antibiotic combinations (Fig. 3C) suggest that different cellular
mechanisms underlie the increased survival rates with these pairs
of drugs. However, the results of our time-lapse image analysis
suggest a new perspective on how and when cells can elude killing
by antibiotics. This method allowed for the examination of cell
growth as distinct rates of elongation and division (Fig. 4). The
similar reductions in division rates produced by different bacte-
riostatic-bactericidal drug pairs could be the basis of antagonism.
In relation to the morphological effects we quantified, other anti-
biotics are capable of eliciting changes in cell shape. For example,
members of the beta-lactam class induce cell lysis via a bulge-
mediated process in which the cytosol leaks out through defects
produced in the peptidoglycan layer (38). Future work should
consider whether such structural effects are capable of modulating
rates of cell division and therefore would be similarly capable of
producing antagonism.
In a complementary study, a separate element of bacterial
physiology has been found to be important in killing by antibiot-
ics. Allison and colleagues distinguished metabolic activity from
growth as a factor that potentiates the killing of dormant cells by
aminoglycosides (39). Determining conditions that affect specific
aspects of cell physiology, such as increasing metabolic activity or
inhibiting division, could be important for designing new antibi-
otics or increasing the efficiency of our currently available drugs.
Our results urge caution before forming general assumptions
regarding the effects of drug interactions. Although our studies of
bacteriostatic and bactericidal drugs reveal pervasive antagonism
in growth and death rates, the variety of morphological responses
we observe may lead to antibiotic combination-specific fitness
effects. Furthermore, the bacteriostatic/bactericidal classification
Ocampo et al.
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system varies across organisms and even across drug concentra-
tions, and the interactions between drugs may similarly shift. As-
sessing in vitro drug interactions across a wide range of concen-
trations can guide in vivo studies, where variables such as
absorption rates, elimination rates, and dosing regimens may lead
to fluctuations in concentrations (6). Additionally, other variables
intrinsic to the in vivo environment, such as changes in pH across
body compartments, may result in changes to drug interactions
that cannot be predicted in in vitro experiments.
Antibiotic combination therapy remains an important option
as a treatment strategy aimed at controlling the rise of resistance.
As this goal is approached, the single-cell dynamics we observed
with different antagonistic drug pairs indicate that closer exami-
nation of the effects of antibiotics on individual components of
bacterial physiology would aid in our understanding and utiliza-
tion of drug combinations for more bacterial infections.
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